tipranavir cost effective in treatment-experienced hiv

Inpharma 1546 - 15 Jul 2006 Tipranavir cost effective in treatment-experienced HIV The incremental cost-effectiveness ratio (ICER) for ritonavir-boosted tipranavir falls within the acceptable range of $US50 000–$US100 000 for treatment- experienced patients with HIV infections, according to a study * presented at the 11th International Meeting of the International Society for Pharmacoeconomics and Outcomes Research. They used a Markov model to assess the cost effectiveness of the ritonavir-boosted tipranavir using data from the 48-week RESIST 1 (n = 620) and 2 (n = 863) trials, in which the safety and efficacy of ritonavir-boosted tipranavir were compared with ritonavir-boosted comparator protease inhibitors (PI) in patents who had received at least two PI-based regimens and three classes of antiretrovirals; comparator PIs included amprenavir, fosamprenavir, lopinavir, indinavir or saquinavir. Costs ** were estimated in 2005 US dollars from the US payer perspective; costs and life expectancy were discounted at 3%. Over 5 years, the rate of AIDS-defining events decreased by 12.35% for patients receiving ritonavir- boosted tipranavir, which led to cost offsets of $US7086. Compared with comparator PI recipients, tipranavir recipients gained 7.7 quality-adjusted life months, at an additional cost of $US36 188. The ICER of ritonavir-boosted tipranavir versus ritonavir-boosted comparator PI was $US56 315 per quality-adjusted life year (QALY) gained. ICER decreased to $US49 563 per QALY gained for patients who had not received enfuvirtide as an optimised background regimen. Sensitivity analyses showed that the ICER of ritonavir- boosted tipranavir was in the range of $US48 874–$US60 325 per QALY gained. * sponsored by Boehringer Ingelheim ** Costs included drug prices and costs of patient monitoring and AIDS-defining events. Simpson KN, et al. Cost effectiveness of tipranavir in treatment-experienced HIV patients in the USA. Value in Health 9: 156 (plus poster) abstr. PIN10, No. 3, May-Jun 2006 801066770 1 Inpharma 15 Jul 2006 No. 1546 1173-8324/10/1546-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved

Post on 13-Dec-2016

212 views

Category:

Documents

0 download

Report

Download

Embed Size (px):

TRANSCRIPT

Inpharma 1546 - 15 Jul 2006

Tipranavir cost effective intreatment-experienced HIV

The incremental cost-effectiveness ratio (ICER) forritonavir-boosted tipranavir falls within the acceptablerange of $US50 000–$US100 000 for treatment-experienced patients with HIV infections, according to astudy* presented at the 11th International Meeting ofthe International Society for Pharmacoeconomics andOutcomes Research.

They used a Markov model to assess the costeffectiveness of the ritonavir-boosted tipranavir usingdata from the 48-week RESIST 1 (n = 620) and 2(n = 863) trials, in which the safety and efficacy ofritonavir-boosted tipranavir were compared withritonavir-boosted comparator protease inhibitors (PI) inpatents who had received at least two PI-based regimensand three classes of antiretrovirals; comparator PIsincluded amprenavir, fosamprenavir, lopinavir, indinaviror saquinavir. Costs** were estimated in 2005 US dollarsfrom the US payer perspective; costs and life expectancywere discounted at 3%.

Over 5 years, the rate of AIDS-defining eventsdecreased by 12.35% for patients receiving ritonavir-boosted tipranavir, which led to cost offsets of$US7086. Compared with comparator PI recipients,tipranavir recipients gained 7.7 quality-adjusted lifemonths, at an additional cost of $US36 188. The ICER ofritonavir-boosted tipranavir versus ritonavir-boostedcomparator PI was $US56 315 per quality-adjusted lifeyear (QALY) gained. ICER decreased to $US49 563 perQALY gained for patients who had not receivedenfuvirtide as an optimised background regimen.Sensitivity analyses showed that the ICER of ritonavir-boosted tipranavir was in the range of$US48 874–$US60 325 per QALY gained.* sponsored by Boehringer Ingelheim** Costs included drug prices and costs of patient monitoring andAIDS-defining events.

Simpson KN, et al. Cost effectiveness of tipranavir in treatment-experienced HIVpatients in the USA. Value in Health 9: 156 (plus poster) abstr. PIN10, No. 3,May-Jun 2006 801066770

Challenges Experienced by HIV/AIDS ... - tbj.ssu.ac.irtbj.ssu.ac.ir/article-1-2792-fa.pdf · Downloaded from tbj.ssu.ac.ir at 22:52 IRDT on Wednesday June 17th 2020 [ DOI: 10.18502/tbj.v18i5.2282

1 Managing the Treatment-Experienced Patient Eric S. Daar, MD Professor of Medicine, David Geffen School of Medicine at UCLA Chief, Division of HIV Medicine,

Perawatan HIV Komprehensif (MA HIV)

NORMAS NACIONALES DE TRATAMIENTO ANTIRRETROVIRAL … · TARGA Tratamiento antirretroviral de gran actividad TDF Tenofovir TPV Tipranavir 3TC Lamivudina 4 Normas Nacionales de tratamiento

Induction: Drug Transporters versus Enzymes · Transporter Inducer P-gp Avasimibe, carbamazepine, phenytoin, rifampin, St. John’s wort, tipranavir/ritonavir BCRP Not known OATP1B1

Specific Aims Workshop - University of Alabama at Birmingham...Oct 10, 2017 · Facilitators (experienced HIV researchers and grant writers) – Janet Turan – public health, qual

Efficacy and Safety of Maraviroc in Antiretroviral- Experienced Patients Infected With CCR5-Tropic HIV-1: 48-Week Results of MOTIVATE 1 J Lalezari 1, J

DUET-1 and DUET-2: TMC125 versus placebo in treatment-experienced HIV-1-infected patients DUET-1: Anthony Mills, Pedro Cahn, Beatriz Grinsztejn, Richard

TB HIV treatment cascade judith - Southern African … Mwansa-Kambafwile - TB HIV treatment... · TB/HIV treatment cascade ... offered HIV test if status unknown HIV- HIV+ (CTX given)

Cost-Effectiveness Analysis of Raltegravir in Treatment- Experienced HIV Patients in Spain Mohammad A. Chaudhary, Santiago Moreno, Ritesh N. Kumar, Gonzalo

Overcoming Treatment Challenges in the Treatment-Experienced Patient With HIV A Review of New Antiretroviral Agents Daniel S. Berger, MD Medical Director,

Guidelines to reduce stigma · TB Stigma (Tuberculosis) DDS Men-tal illness DDS Men-tal illness Self stigma ISMI Berger (HIV/AIDS) CATIS (children) TB Stigma (Tuberculosis) Experienced